15/09/2015 07:13:07

CORRECTION: CROSSJECT enters into partnering agreement with Sayre Therapeutics to commercialize ZENEO® Methotrexate in India

This is a correction of the announcement from 17:45 14.09.2015 CEST. Reason for the correction: In "About Sayre Therapeutics", one should have read that Shukrit and Vandana are co-founders at Sayre Therapeutics and not at Biocon. This version replaces and cancels the previous one.

CROSSJECT enters into partnering agreement with Sayre Therapeutics to commercialize ZENEO® Methotrexate in India

Chenôve (France) and Bangalore (India), September 14 2015 - CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) , the creator of ZENEO®, a needle-free injection system developed to be used with a portfolio of well-known drugs announces today a partnering agreement with Sayre Therapeutics to commercialise ZENEO® Methotrexate in India. The filing of the marketing authorisation files of this innovative product for the treatment of rheumatoid arthritis in the region, is anticipated early 2017.

 

The agreement provides Sayre Therapeutics with exclusive distribution and marketing rights  in India, Bangladesh, Sri Lanka and Nepal. In return, CROSSJECT will receive a share from 20% to 40% of the revenues generated from the product. Sayre Therapeutics has committed to minimum levels of volumes and marketing investment.

 

Patrick Alexandre, CROSSJECT's founder and CEO said: "The Indian market has been chosen due to the pricing environment which will allow us to generate attractive returns. This is a high margin niche market thanks to the free pricing mechanisms in this area. This deal will allow us to capture value from ZENEO® without any further investments. It also allows us to continue to focus our  commercial strategy on North America and Europe. We are convinced that Sayre Therapeutics with its entrepreneurial spirit, experienced team, including its sales force, has all the attributes needed to successfully  commercialise ZENEO® Methotrexate."

A spokesperson for Sayre Therapeutics comments: "This collaboration with CROSSJECT will further reinforce our product portfolio, particularly for the home care market. Sayre Therapeutics is now well established  through the Indian subcontinent and South Asia, and we are now ready to focus on chronic diseases  such as  rheumatoid arthritis by providing patients with a needle-free injection system that is easy and safe to use."

 

About Crossject  ·  www.crossject.com

Crossject is using its world-leading needle-free injection system, ZENEO(TM) to develop an attractive pipeline of high-value SUPERGENERICS or New Therapeutics Entities. These needle-free products, which are based on well-known injectable drugs (chemicals & biologics), are designed to enhance patient safety, compliance and comfort.

Crossject's needle-free, pre-filled, single-use ZENEO (TM) injection systems are unique in that they can be tailored to deliver drugs intradermally, subcutaneously and intramuscularly. This means that ZENEO(TM) can allow a wide range of drugs and vaccines for a broad range of indications to be developed and approved in a very short period. Outside its own portfolio of SUPERGENERICS, Crossject anticipates partnering ZENEO with other pharma/biotech looking to improve the life cycle management of their key drugs or biologics.

CROSSJECT is listed on Alternext Paris (Mnemo : ALCJ, ISIN : FR0011716265)

 

About Sayre Therapeutics

Sayre Therapeutics is specialized in innovative treatments and medical devices commercialization in South Asia. The founders experience and its dynamic team have allowed Sayre to rapidly develop its product portfolio.

 Follow us on Twitter @Crossject

 

Contacts

       

Patrick Alexandre / Timothée Muller

info@crossject.com

Citigate Dewe Rogerson

Laurence Bault /Lucie Larguier

+33 (0)1 53 32 84 78 / 84 75

laurence.bault@citigate.fr

 

lucie.larguier@citigate.fr

PDF version


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: CROSSJECT via Globenewswire

HUG#1952036

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Apr
 
Et opgør med Finanstilsynet er tvingende nødvendigt, hvis tilliden til markedet ikke skal lægges øde..
28
08:03
OMXC25
Som tidligere påvist kan bulls køre hen over hvilken som helt bear. Hvis de altså vil. Det kræver at..
25
15 Apr
OMXC25
Virkelig intelligent indlæg. En masse om at markedet er på vej til nedtur, men sjovt nok ikke så meg..
24
18 Apr
 
LÆS NU FOR HELVEDE NOGEN AF DE 38000 indlæg som siger at børsen er nede!   Det er kraftstejleme da u..
21
19 Apr
BAVA
      Vedr. shortsqeeze mm. og den ekstreme kursmanipulation der dagligt foregår på Nasdaq Kbhvn. T..
19
20 Apr
VWS
Vestas har en ordrerbeholdning større end de nogensinde har haft, og de sendte en næsten færdigjort ..
18
18 Apr
 
Det er en katastrofe ! Hvis det fortsætter ret meget længere er vi allesammen nødt til at gå ud og l..
16
20 Apr
VWS
hvornår kommer analysen?
15
17 Apr
LAUR
An aktie man aldrig skal eje. Ejerne trækker store summer ud, at en virksomhed der kæmper for overle..
14
19 Apr
 
Hej alle,   Jeg lavede et lille indlæg på Stolt-Nielsen for nylig hvor jeg desværre – og det beklage..
13

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Pomerantz Law Firm Announces the Filing of a Class Action against Myriad Genetics, Inc. and Certain Officers – MYGN
2
Jostens Unveils North Dakota State University Championship Rings and Fan Jewelry Collection
3
We sat down with Canadian millennial entrepreneur, Logan McLellan, to discuss the importance of using social media in modern day business
4
SYNACOR SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Synacor, Inc. - SYNC
5
Straus Family Creamery’s Sustainability Programs Signal Pioneering Organic Company’s Continued Innovation

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 April 2018 20:15:39
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20180417.1 - EUROWEB7 - 2018-04-21 21:15:39 - 2018-04-21 20:15:39 - 1000 - Website: OKAY